Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Lori Julin Wirth, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Krane JF, Cibas ES, Endo M, Marqusee E, Hu MI, Nasr CE, Waguespack SG, Wirth LJ, Kloos RT. The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: Insights to inform clinical decision-making from a fine-needle aspiration sample. Cancer Cytopathol. 2020 Jun 16. PMID: 32543766.
    Citations:    
  2. Dias-Santagata D, Lennerz JK, Sadow PM, Frazier RP, Raju SG, Henry D, Chung T, Kherani J, Rothenberg SM, Wirth LJ. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 2020 May 19. PMID: 32292131.
    Citations:    
  3. Nakaguro M, Tada Y, Faquin WC, Sadow PM, Wirth LJ, Nagao T. Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. Cancer Cytopathol. 2020 May 18. PMID: 32421944.
    Citations:    
  4. Delord JP, Argilés G, Fayette J, Wirth L, Kasper S, Siena S, Mesia R, Berardi R, Cervantes A, Dekervel J, Zhao S, Sun Y, Hao HX, Tiedt R, Vicente S, Myers A, Siu LL. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. Invest New Drugs. 2020 May 14. PMID: 32410080.
    Citations:    
  5. Capdevila J, Wirth LJ, Ernst T, Ponce Aix S, Lin CC, Ramlau R, Butler MO, Delord JP, Gelderblom H, Ascierto PA, Fasolo A, Führer D, Hütter-Krönke ML, Forde PM, Wrona A, Santoro A, Sadow PM, Szpakowski S, Wu H, Bostel G, Faris J, Cameron S, Varga A, Taylor M. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 May 04; JCO1902727. PMID: 32364844.
    Citations:    
  6. Hillier K, Hughes A, Shamberger RC, Shusterman S, Perez-Atayde AR, Wassner AJ, Iafrate AJ, Dubuc A, Janeway KA, Rothenberg SM, Cox MC, Randolph GW, Wirth LJ, Tsai H, Church A, DuBois SG. A Novel ALK Fusion in Pediatric Medullary Thyroid Carcinoma. Thyroid. 2019 11; 29(11):1704-1707. PMID: 31650892.
    Citations:    
  7. Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG. Analytical and Clinical Validation of Expressed Variants and Fusions From the Whole Transcriptome of Thyroid FNA Samples. Front Endocrinol (Lausanne). 2019; 10:612. PMID: 31572297.
    Citations:    
  8. Koenigs MB, Lefranc-Torres A, Bonilla-Velez J, Patel KB, Hayes DN, Glomski K, Busse PM, Chan AW, Clark JR, Deschler DG, Emerick KS, Hammon RJ, Wirth LJ, Lin DT, Mroz EA, Faquin WC, Rocco JW. Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy. J Natl Cancer Inst. 2019 09 01; 111(9):933-942. PMID: 30715409.
    Citations:    
  9. Ameri AH, Mooradian MJ, Emerick KS, Park JC, Wirth LJ, Asgari MM, Tsao H, Lawrence D, Sullivan RJ, Demehri S. Immunotherapeutic strategies for cutaneous squamous cell carcinoma prevention in xeroderma pigmentosum. Br J Dermatol. 2019 11; 181(5):1095-1097. PMID: 31102460.
    Citations:    
  10. Ishida E, Lee J, Campbell JS, Chakravarty PD, Katori Y, Ogawa T, Johnson L, Mukhopadhyay A, Faquin WC, Lin DT, Wirth LJ, Pierce RH, Pai SI. Intratumoral delivery of an HPV vaccine elicits a broad anti-tumor immune response that translates into a potent anti-tumor effect in a preclinical murine HPV model. Cancer Immunol Immunother. 2019 Aug; 68(8):1273-1286. PMID: 31243491.
    Citations:    
  11. Wirth LJ, Burtness B, Nathan CO, Grégoire V, Richmon J. Point/Counterpoint: Do We De-escalate Treatment of HPV-Associated Oropharynx Cancer Now? And How? Am Soc Clin Oncol Educ Book. 2019 Jan; 39:364-372. PMID: 31099643.
    Citations:    
  12. Wirth LJ. Still Perfecting Radioiodine in Thyroid Cancer, After All These Years. J Clin Endocrinol Metab. 2019 05 01; 104(5):1655-1657. PMID: 30462299.
    Citations:    Fields:    
  13. Irwin KE, Moy B, Fields LE, Callaway CA, Park ER, Wirth L. Expanding Access to Cancer Clinical Trials for Patients With Mental Illness. J Clin Oncol. 2019 06 20; 37(18):1524-1528. PMID: 30986118.
    Citations:    
  14. Thierauf J, Ramamurthy N, Jo VY, Robinson H, Frazier RP, Gonzalez J, Pacula M, Dominguez Meneses E, Nose V, Nardi V, Dias-Santagata D, Le LP, Lin DT, Faquin WC, Wirth LJ, Hess J, Iafrate AJ, Lennerz JK. Clinically Integrated Molecular Diagnostics in Adenoid Cystic Carcinoma. Oncologist. 2019 10; 24(10):1356-1367. PMID: 30926674.
    Citations:    
  15. Gunda V, Gigliotti B, Ashry T, Ndishabandi D, McCarthy M, Zhou Z, Amin S, Lee KE, Stork T, Wirth L, Freeman GJ, Alessandrini A, Parangi S. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer. Int J Cancer. 2019 05 01; 144(9):2266-2278. PMID: 30515783.
    Citations:    Fields:    
  16. Haddad RI, Nasr C, Bischoff L, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Goldner W, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McIver B, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sippel R, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Wong RJ, Johnson-Chilla A, Hoffmann KG, Gurski LA. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. J Natl Compr Canc Netw. 2018 12; 16(12):1429-1440. PMID: 30545990.
    Citations:    Fields:    
  17. Tahara M, Brose MS, Wirth LJ, Suzuki T, Miyagishi H, Fujino K, Dutcus CE, Gianoukakis A. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur J Cancer. 2019 01; 106:61-68. PMID: 30471649.
    Citations:    Fields:    
  18. Park JC, Chan AW, Wirth LJ. Controversies Regarding the Management of Locoregionally Advanced Nasopharyngeal Carcinoma: Are We Asking the Right Questions? J Oncol Pract. 2018 10; 14(10):603-605. PMID: 30312565.
    Citations:    Fields:    
  19. Gopal RK, Kübler K, Calvo SE, Polak P, Livitz D, Rosebrock D, Sadow PM, Campbell B, Donovan SE, Amin S, Gigliotti BJ, Grabarek Z, Hess JM, Stewart C, Braunstein LZ, Arndt PF, Mordecai S, Shih AR, Chaves F, Zhan T, Lubitz CC, Kim J, Iafrate AJ, Wirth L, Parangi S, Leshchiner I, Daniels GH, Mootha VK, Dias-Santagata D, Getz G, McFadden DG. Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma. Cancer Cell. 2018 08 13; 34(2):242-255.e5. PMID: 30107175.
    Citations: 1     Fields:    
  20. Degboe A, Knight SL, Halling K, Trigg A, Al-Zubeidi T, Aldhouse N, Kitchen H, Wirth L, Rogers SN. Patients' experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study. J Patient Rep Outcomes. 2017; 2:33. PMID: 30148250.
    Citations:    
  21. Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018 08 01; 29(8):1869-1876. PMID: 29912274.
    Citations: 2     Fields:    
  22. Subbiah V, Gainor JF, Rahal R, Brubaker JD, Kim JL, Maynard M, Hu W, Cao Q, Sheets MP, Wilson D, Wilson KJ, DiPietro L, Fleming P, Palmer M, Hu MI, Wirth L, Brose MS, Ou SI, Taylor M, Garralda E, Miller S, Wolf B, Lengauer C, Guzi T, Evans EK. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. Cancer Discov. 2018 07; 8(7):836-849. PMID: 29657135.
    Citations: 3     Fields:    
  23. Wirth LJ, Tahara M, Robinson B, Francis S, Brose MS, Habra MA, Newbold K, Kiyota N, Dutcus CE, Mathias E, Guo M, Sherman SI, Schlumberger M. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer. 2018 06 01; 124(11):2365-2372. PMID: 29656442.
    Citations: 1     Fields:    
  24. Lubitz CC, Zhan T, Gunda V, Amin S, Gigliotti BJ, Fingeret AL, Holm TM, Wachtel H, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ, Parangi S. Circulating BRAFV600E Levels Correlate with Treatment in Patients with Thyroid Carcinoma. Thyroid. 2018 03; 28(3):328-339. PMID: 29378474.
    Citations:    Fields:    Translation:HumansAnimals
  25. Byrd SA, Xu MJ, Cass LM, Wehrmann DJ, Naunheim M, Christopher K, Dombrowski JJ, Walker RJ, Wirth L, Clark J, Busse P, Chan A, Deschler DG, Emerick K, Lin DT, Varvares MA. Oncologic and functional outcomes of pretreatment tracheotomy in advanced laryngeal squamous cell carcinoma: A multi-institutional analysis. Oral Oncol. 2018 03; 78:171-176. PMID: 29496047.
    Citations:    Fields:    
  26. Addison D, Lawler PR, Emami H, Janjua SA, Staziaki PV, Hallett TR, Hennessy O, Lee H, Szilveszter B, Lu M, Mousavi N, Nayor MG, Delling FN, Romero JM, Wirth LJ, Chan AW, Hoffmann U, Neilan TG. Incidental Statin Use and the Risk of Stroke or Transient Ischemic Attack after Radiotherapy for Head and Neck Cancer. J Stroke. 2018 Jan; 20(1):71-79. PMID: 29402065.
    Citations: 1     
  27. Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clin Cancer Res. 2018 04 01; 24(7):1546-1553. PMID: 29301825.
    Citations: 1     Fields:    
  28. Schlumberger M, Elisei R, Müller S, Schöffski P, Brose M, Shah M, Licitra L, Krajewska J, Kreissl MC, Niederle B, Cohen EEW, Wirth L, Ali H, Clary DO, Yaron Y, Mangeshkar M, Ball D, Nelkin B, Sherman S. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol. 2017 Nov 01; 28(11):2813-2819. PMID: 29045520.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  29. Mattox AK, Lee J, Westra WH, Pierce RH, Ghossein R, Faquin WC, Diefenbach TJ, Morris LG, Lin DT, Wirth LJ, Lefranc-Torres A, Ishida E, Chakravarty PD, Johnson L, Zeng YC, Chen H, Poznansky MC, Iyengar NM, Pai SI. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4+ TILs in the Presence of PD-L1+ TAMs. Cancer Res. 2017 11 15; 77(22):6365-6374. PMID: 28947422.
    Citations: 1     Fields:    Translation:HumansCells
  30. Addison D, Seidelmann SB, Janjua SA, Emami H, Staziaki PV, Hallett TR, Szilveszter B, Lu MT, Cambria RP, Hoffmann U, Chan AW, Wirth LJ, Neilan TG. Human Papillomavirus Status and the Risk of Cerebrovascular Events Following Radiation Therapy for Head and Neck Cancer. J Am Heart Assoc. 2017 Aug 30; 6(9). PMID: 28855164.
    Citations: 1     Fields:    Translation:HumansCells
  31. Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol. 2017 Oct 10; 35(29):3315-3321. PMID: 28817373.
    Citations:    
  32. Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017 May 10; 35(14):1542-1549. PMID: 28328302.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  33. Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017 Jul 15; 123(14):2642-2650. PMID: 28222215.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  34. Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017 Apr; 56(1):121-128. PMID: 28155175.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  35. Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. PMID: 28148207.
    Citations: 12     Fields:    
  36. Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB. Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol. 2016; 6:232. PMID: 27843803.
    Citations: 8     
  37. El-Jawahri A, Quinn K, Arcikowski L, Chan G, Viscosi E, Doherty C, Clark JR, Temel JS, Wirth LJ. A two-group study to evaluate the impact of an educational handbook in the care of patients with head and neck cancer (HNC). J Clin Oncol. 2016 Oct 09; 34(26_suppl):228. PMID: 28156655.
    Citations:    
  38. El-Jawahri A, Quinn K, Arcikowski L, Chan G, Viscosi E, Doherty C, Clark JR, Wirth LJ, Temel JS. Patient reported outcomes (PROs) in patients with human papilloma virus (HPV) positive versus negative head and neck cancer (HNC). J Clin Oncol. 2016 Oct 09; 34(26_suppl):87. PMID: 28156440.
    Citations:    
  39. Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J. A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3641-3649. PMID: 27648727.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  40. Robinson B, Schlumberger M, Wirth LJ, Dutcus CE, Song J, Taylor MH, Kim SB, Krzyzanowska MK, Capdevila J, Sherman SI, Tahara M. Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer. J Clin Endocrinol Metab. 2016 11; 101(11):4103-4109. PMID: 27548104.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  41. Wirth LJ, Dakhil S, Kornek G, Axelrod R, Adkins D, Pant S, O'Brien P, Debruyne PR, Oliner KS, Dong J, Murugappan S. PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2016 10; 61:31-40. PMID: 27688102.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  42. Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer. 2016 Dec 15; 122(24):3803-3811. PMID: 27525588.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  43. Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EE, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer. 2016 Dec 15; 122(24):3856-3864. PMID: 27525386.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  44. Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1272-82. PMID: 27460442.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  45. Ritterhouse LL, Wirth LJ, Randolph GW, Sadow PM, Ross DS, Liddy W, Lennerz JK. ROS1 Rearrangement in Thyroid Cancer. Thyroid. 2016 06; 26(6):794-7. PMID: 27089969.
    Citations: 2     Fields:    Translation:Humans
  46. Wirth L, Dorn F, Wege M, Zemlin M, Lemmer B, Gorbey S, Timmesfeld N, Maier RF. Effects of standardized acoustic stimulation in premature infants: a randomized controlled trial. J Perinatol. 2016 06; 36(6):486-92. PMID: 26890554.
    Citations:    Fields:    Translation:Humans
  47. Wirth LJ. Cetuximab in Human Papillomavirus-Positive Oropharynx Carcinoma. J Clin Oncol. 2016 Apr 20; 34(12):1289-91. PMID: 26884569.
    Citations: 1     Fields:    Translation:HumansCells
  48. Rothenberg SM, Daniels GH, Wirth LJ. Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response. Clin Cancer Res. 2015 Dec 15; 21(24):5640-1. PMID: 26672087.
    Citations: 7     Fields:    Translation:Humans
  49. Lubitz CC, Parangi S, Holm TM, Bernasconi MJ, Schalck AP, Suh H, Economopoulos KP, Gunda V, Donovan SE, Sadow PM, Wirth LJ, Sullivan RJ, Panka DJ. Detection of Circulating BRAF(V600E) in Patients with Papillary Thyroid Carcinoma. J Mol Diagn. 2016 Jan; 18(1):100-8. PMID: 26631873.
    Citations: 3     Fields:    Translation:HumansCells
  50. Kiyota N, Schlumberger M, Muro K, Ando Y, Takahashi S, Kawai Y, Wirth L, Robinson B, Sherman S, Suzuki T, Fujino K, Gupta A, Hayato S, Tahara M. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Sci. 2015 Dec; 106(12):1714-21. PMID: 26426092.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  51. Haddad RI, Lydiatt WM, Ball DW, Busaidy NL, Byrd D, Callender G, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, McCaffrey JC, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Smallridge RC, Sturgeon C, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Anaplastic Thyroid Carcinoma, Version 2.2015. J Natl Compr Canc Netw. 2015 Sep; 13(9):1140-50. PMID: 26358798.
    Citations: 13     Fields:    Translation:Humans
  52. Willers H, Gheorghiu L, Liu Q, Efstathiou JA, Wirth LJ, Krause M, von Neubeck C. DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol. 2015 Oct; 25(4):237-50. PMID: 26384272.
    Citations: 13     Fields:    Translation:Humans
  53. Schlumberger M, Tahara M, Wirth LJ. Lenvatinib in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 05 07; 372(19):1868. PMID: 25946295.
    Citations:    Fields:    Translation:Humans
  54. Clayman GL, Wirth LJ. New and emerging therapeutic options for thyroid carcinoma: A&A discussion. Clin Adv Hematol Oncol. 2015 Apr; 13(4 Suppl 4):17. PMID: 26430871.
    Citations: 1     Fields:    Translation:Humans
  55. Wirth LJ. Targeted therapy for advanced or metastatic differentiated thyroid carcinoma. Clin Adv Hematol Oncol. 2015 Apr; 13(4 Suppl 4):9-16. PMID: 26430870.
    Citations:    Fields:    Translation:Humans
  56. Shah JP, Clayman GL, Wirth LJ. New and emerging therapeutic options for thyroid carcinoma. Clin Adv Hematol Oncol. 2015 Apr; 13(4 Suppl 4):3-17, 1; quiz 2 p following 18. PMID: 25856096.
    Citations:    
  57. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12; 372(7):621-30. PMID: 25671254.
    Citations: 157     Fields:    Translation:HumansCTClinical Trials
  58. Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 01; 21(7):1566-73. PMID: 25573383.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  59. Rothenberg SM, McFadden DG, Palmer EL, Daniels GH, Wirth LJ. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib. Clin Cancer Res. 2015 Mar 01; 21(5):1028-35. PMID: 25549723.
    Citations: 22     Fields:    Translation:Humans
  60. Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 01; 21(5):1002-9. PMID: 25501576.
    Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
  61. Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, Ehya H, Haymart M, Hoh C, Hunt JP, Iagaru A, Kandeel F, Kopp P, Lamonica DM, Lydiatt WM, McCaffrey J, Moley JF, Parks L, Raeburn CD, Ridge JA, Ringel MD, Scheri RP, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ, Hoffmann KG, Hughes M. Thyroid carcinoma, version 2.2014. J Natl Compr Canc Netw. 2014 Dec; 12(12):1671-80; quiz 1680. PMID: 25505208.
    Citations: 32     Fields:    Translation:Humans
  62. Chong CR, Wirth LJ, Nishino M, Chen AB, Sholl LM, Kulke MH, McNamee CJ, Jänne PA, Johnson BE. Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors. Lung Cancer. 2014 Nov; 86(2):241-6. PMID: 25218177.
    Citations: 15     Fields:    Translation:Humans
  63. Bauman J, Wirth L. Human Papillomavirus and Oropharyngeal Squamous Cell Carcinoma of the Head and Neck: A Growing Epidemic. Adolesc Med State Art Rev. 2014 Aug; 25(2):489-501. PMID: 27132327.
    Citations:    Fields:    Translation:HumansPHPublic Health
  64. Haddad R, Sherman SI, Shah JP, Wirth LJ. New frontiers and treatment paradigms for thyroid carcinoma. Clin Adv Hematol Oncol. 2014 Jul; 12(7 Suppl 14):3-21; quiz 22. PMID: 25768715.
    Citations:    Fields:    Translation:Humans
  65. Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Dutcus CE, de Las Heras B, Zhu J, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Sherman SI. A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA6008. PMID: 28141975.
    Citations:    
  66. Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments. Cancer. 2014 09 01; 120(17):2694-703. PMID: 24844950.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  67. Gross ND, Bauman JE, Gooding WE, Denq W, Thomas SM, Wang L, Chiosea S, Hood BL, Flint MS, Sun M, Conrads TP, Ferris RL, Johnson JT, Kim S, Argiris A, Wirth L, Nikiforova MN, Siegfried JM, Grandis JR. Erlotinib, erlotinib-sulindac versus placebo: a randomized, double-blind, placebo-controlled window trial in operable head and neck cancer. Clin Cancer Res. 2014 Jun 15; 20(12):3289-98. PMID: 24727329.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  68. McBride SM, Rothenberg SM, Faquin WC, Chan AW, Clark JR, Ellisen LW, Wirth LJ. Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma. Head Neck. 2014 Aug; 36(8):1181-8. PMID: 23852799.
    Citations: 8     Fields:    Translation:Humans
  69. Wirth LJ. Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum. Cancer Prev Res (Phila). 2014 Mar; 7(3):279-82. PMID: 24441671.
    Citations: 1     Fields:    Translation:Humans
  70. McBride SM, Busse PM, Clark JR, Wirth LJ, Ancukiewicz M, Chan AW. Long-term survival after distant metastasis in patients with oropharyngeal cancer. Oral Oncol. 2014 Mar; 50(3):208-12. PMID: 24387975.
    Citations: 7     Fields:    Translation:Humans
  71. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013 Oct 10; 31(29):3639-46. PMID: 24002501.
    Citations: 175     Fields:    Translation:HumansCTClinical Trials
  72. Rosen LS, Lipton L, Price TJ, Belman ND, Boccia RV, Hurwitz HI, Stephenson JJ, Wirth LJ, McCoy S, Hei YJ, Hsu CP, Tebbutt NC. The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer. 2013 May 16; 13:242. PMID: 23679351.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  73. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila). 2013 May; 6(5):410-8. PMID: 23639862.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  74. Anderson RT, Linnehan JE, Tongbram V, Keating K, Wirth LJ. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. Thyroid. 2013 Apr; 23(4):392-407. PMID: 23294230.
    Citations: 16     Fields:    Translation:Humans
  75. Wirth LJ, Ross DS, Randolph GW, Cunnane ME, Sadow PM. Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid. N Engl J Med. 2013 Feb 14; 368(7):664-73. PMID: 23406032.
    Citations: 2     Fields:    Translation:Humans
  76. Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, Li Y, Wirth LJ, Dias-Santagata D. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clin Cancer Res. 2013 Jan 15; 19(2):480-90. PMID: 23186780.
    Citations: 23     Fields:    Translation:Humans
  77. Wirth LJ, Plotkin SR, Emerick KS, Cunnane ME, Faquin WC. Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer. N Engl J Med. 2012 Sep 20; 367(12):1136-47. PMID: 22992078.
    Citations: 3     Fields:    Translation:Humans
  78. Pacini F, Ito Y, Luster M, Pitoia F, Robinson B, Wirth L. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. Expert Rev Endocrinol Metab. 2012 Sep; 7(5):541-554. PMID: 30780891.
    Citations:    
  79. Schoenfeld JD, Odejide OO, Wirth LJ, Chan AW. Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report. Anticancer Res. 2012 May; 32(5):1743-6. PMID: 22593455.
    Citations: 5     Fields:    Translation:Humans
  80. Houvras Y, Wirth LJ. Cabozantinib in medullary thyroid carcinoma: time to focus the spotlight on this rare disease. J Clin Oncol. 2011 Jul 01; 29(19):2616-8. PMID: 21606409.
    Citations: 1     Fields:    Translation:Humans
  81. Wirth LJ, Nardi V, Juric D, Cosper AK, Bergethon K, Scialabba V, Borger DR, Iafrate AJ, Ellisen LW, Deschler D, Zhao D, Sadow PM, Dias-Santagata D. Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. J Clin Oncol. 2011 May 20; 29(15_suppl):5579. PMID: 28022120.
    Citations:    
  82. Tebbutt NC, Lipton LR, Price TJ, Belman ND, Boccia RV, Hurwitz H, Stephenson J, Wirth LJ, McCoy S, Sikorski R, Hei YJ, Rosen LS. The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors. J Clin Oncol. 2011 May 20; 29(15_suppl):e13555. PMID: 28022741.
    Citations:    
  83. Sher DJ, Balboni TA, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Tishler RB. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys. 2011 Aug 01; 80(5):1405-11. PMID: 21177045.
    Citations: 6     Fields:    Translation:Humans
  84. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey JC, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Thyroid carcinoma. J Natl Compr Canc Netw. 2010 Nov; 8(11):1228-74. PMID: 21081783.
    Citations: 56     Fields:    Translation:Humans
  85. Sher DJ, Haddad RI, Norris CM, Posner MR, Wirth LJ, Goguen LA, Annino D, Balboni T, Allen A, Tishler RB. Efficacy and toxicity of reirradiation using intensity-modulated radiotherapy for recurrent or second primary head and neck cancer. Cancer. 2010 Oct 15; 116(20):4761-8. PMID: 20572036.
    Citations: 10     Fields:    Translation:Humans
  86. Cleary JM, Sadow PM, Randolph GW, Palmer EL, Lynch TP, Nikiforov YE, Wirth LJ. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib. J Clin Oncol. 2010 Aug 10; 28(23):e390-2. PMID: 20567012.
    Citations: 3     Fields:    Translation:Humans
  87. Tuttle RM, Ball DW, Byrd D, Daniels GH, Dilawari RA, Doherty GM, Duh QY, Ehya H, Farrar WB, Haddad RI, Kandeel F, Kloos RT, Kopp P, Lamonica DM, Loree TR, Lydiatt WM, McCaffrey J, Olson JA, Parks L, Ridge JA, Shah JP, Sherman SI, Sturgeon C, Waguespack SG, Wang TN, Wirth LJ. Medullary carcinoma. J Natl Compr Canc Netw. 2010 May; 8(5):512-30. PMID: 20495082.
    Citations: 20     Fields:    Translation:Humans
  88. Wirth LJ, Allen AM, Posner MR, Haddad RI, Li Y, Clark JR, Busse PM, Chan AW, Goguen LA, Norris CM, Annino DJ, Tishler RB. Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. Ann Oncol. 2010 Feb; 21(2):342-7. PMID: 19892746.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  89. Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P, Allen A, Mahadevan A, Flynn J, Burke E, Li Y, Tishler RB. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer. 2009 Oct 01; 115(19):4514-23. PMID: 19634161.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  90. Haddad RI, Tishler RB, Norris C, Goguen L, Balboni TA, Costello R, Wirth L, Lorch J, Andreozzi B, Annino D, Posner MR. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009 Sep 20; 27(27):4448-53. PMID: 19704061.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  91. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol. 2009 Aug 10; 27(23):3794-801. PMID: 19564535.
    Citations: 89     Fields:    Translation:HumansCTClinical Trials
  92. Wirth LJ, Fogg M, Wang F, Lorch J, Haddad RI, Posner MR. Epstein-Barr virus (EBV)-specific immunotherapy in nasopharygneal carcinoma (NPC). J Clin Oncol. 2009 May 20; 27(15_suppl):6025. PMID: 27962433.
    Citations:    
  93. Fogg MH, Wirth LJ, Posner M, Wang F. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2009 Mar 03; 106(9):3318-23. PMID: 19211798.
    Citations: 19     Fields:    Translation:HumansCells
  94. Posner MR, Norris CM, Wirth LJ, Shin DM, Cullen KJ, Winquist EW, Blajman CR, Mickiewicz EA, Frenette GP, Plinar LF, Cohen RB, Steinbrenner LM, Freue JM, Gorbunova VA, Tjulandin SA, Raez LE, Adkins DR, Tishler RB, Roessner MR, Haddad RI. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009 May; 20(5):921-7. PMID: 19179556.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  95. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Induction chemotherapy in locally advanced head and neck cancer: a new standard of care? Hematol Oncol Clin North Am. 2008 Dec; 22(6):1155-63, viii. PMID: 19010265.
    Citations: 11     Fields:    Translation:Humans
  96. Lorch JH, Posner MR, Wirth LJ, Haddad RI. Seeking alternative biological therapies: the future of targeted molecular treatment. Oral Oncol. 2009 Apr-May; 45(4-5):447-53. PMID: 19027348.
    Citations: 4     Fields:    Translation:HumansCells
  97. Wirth LJ, Krane JF, Li Y, Othus M, Moran AE, Dorfman DM, Norris CM, Goguen L, Posner MR, Haddad RI, Bertagnolli MM. A pilot surrogate endpoint biomarker study of celecoxib in oral premalignant lesions. Cancer Prev Res (Phila). 2008 Oct; 1(5):339-48. PMID: 19138978.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  98. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008 Jul 03; 359(1):31-42. PMID: 18596272.
    Citations: 137     Fields:    Translation:HumansCTClinical Trials
  99. Caglar HB, Tishler RB, Othus M, Burke E, Li Y, Goguen L, Wirth LJ, Haddad RI, Norris CM, Court LE, Aninno DJ, Posner MR, Allen AM. Dose to larynx predicts for swallowing complications after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):1110-8. PMID: 18468812.
    Citations: 51     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  100. Wirth LJ, Posner MR, Tishler RB, Haddad RI, Clark JR, Goguen L, Norris CM, Annino D, Costello R, Allen AM. Phase I study of panitumumab + chemoradiotherapy (CRT) for head and neck cancer (HNC). J Clin Oncol. 2008 May 20; 26(15_suppl):6007. PMID: 27950670.
    Citations:    
  101. Posner MR, Norris CM, Tishler RB, Wirth LJ, Haddad RI. Sequential therapy for locally advanced larynx and hypopharynx cancer: Subgroup analysis from the TAX 324 Study. J Clin Oncol. 2008 May 20; 26(15_suppl):6031. PMID: 27950564.
    Citations:    
  102. Tishler RB, Posner MR, Wirth LJ, Balboni T, Costello R, Goguen L, Annino D, Livada N, Norris CM, Haddad RI. Cetuximab added to docetaxel, cisplatin, 5-fluorouracil Induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol. 2008 May 20; 26(15_suppl):6001. PMID: 27950667.
    Citations:    
  103. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid. 2008 Mar; 18(3):317-23. PMID: 17985985.
    Citations: 56     Fields:    Translation:HumansCTClinical Trials
  104. Wirth LJ, Posner MR. Recent advances in combined modality therapy for locally advanced head and neck cancer. Curr Cancer Drug Targets. 2007 Nov; 7(7):674-80. PMID: 18045072.
    Citations: 5     Fields:    Translation:Humans
  105. Freedman RA, Wirth LJ, Chirieac LR, Huang EC. Glioblastoma in a patient with early-stage tonsil cancer. J Clin Oncol. 2007 Jul 01; 25(19):2848-50. PMID: 17602090.
    Citations: 2     Fields:    Translation:Humans
  106. Freedman RA, Chirieac LR, Huang EC, Wirth LJ. Glioblastoma in a Patient With Early-Stage Tonsil Cancer. Journal of Clinical Oncology. 2007; 25(19):2848-50.
  107. Mager DL, Haddad RI, Wirth LJ, Haffajee AD. Oral Mucous Membrane Macrobiotica in Health and Oral Squamous Cell Carcinoma. Grand Rounds in Oral-Systemic Medicine. 2007; 2(1):12-8.
  108. Wirth L and Kies M. Nonsurgical Treatment for Laryngeal Carcinoma. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  109. Allen A, Posner M, Haddad R, Wirth L, Burke E, Goguen L, Norris C, Annino D, Tishler R. Swallowing function after IMRT and chemotherapy for head and neck cancer. Proc Am Soc Clin Oncol. 2007; 25(18S):Abstr #6046.
  110. Sherman S, Schlumberger M, Droz JP, Hofmann M. Wirth L, Bastholt, L, Martins R, Licitra L, Shi Y, Stepan D. Initial Results from a Phase 2 Trial of AMG 706 in Patients (pts) with Differentiated Thyroid Cancer (DTC). Proc European Thyroid Association. 2007; 8.
  111. Pacini F, Sherman S, Schlumberger M, Elisei R, Wirth L, Bastholt L, Droz JP, Martins R, Hofmann M, Locati L, Eschenberg M, Stepan D. Exacerbation of Postsurgica; Hypothyroidism During Treatment of Advanced Differentiated (DTC) or Medullary (MTC) Thyroid Carcinoma with AMG 706. Proc European Thyroid Association. 2007; 73.
  112. Sherman SI, Schlumberger MJ, Droz J, Hofmann M, Wirth L, Bastholt L, Martins RG, Licitra L, Shi Y, Stepan DE. Initial results from a phase 2 trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). Proc Am Soc Clin Oncol. 2007; 25(18S):Abstr #6017.
  113. Wirth L and Kies M. Treatment of Recurrent and/or Metastatic Head and Neck Cancer. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  114. Schlumberger M, Elisei R, Sherman S, Bastholt L, Wirth L, Martins R, Licitra L, Jarzab B, Pacini F, Daumerie C, Droz JP, Shi Y, Sun Y-N, Stepan D. Initial Results froma Phase 2 Trial of Motesanib Diphosphate (AMG 706) in Patients (pts) with Medullary Thyroid Carcinoma (MTC). ENDO Society 2007. 2007; Abstr #852315.
  115. Wirth L and Kies M. Adjuvant Chemoradiotherapy for High-Risk Head and Neck Cancer. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  116. Schlumberger M, Elisei R, Sherman S, Bastholt L, Wirth L, Martins R, Licitra L, Jarzab B, Pacini F, Daumerie C, Droz JP, Shi Y, Sun Y-N, Stepan D. Initial Results from a Phase 2 Trial of AMG 706 in Patients (pts) with Medullary Thyroid Cancer (MTC). Proc European Thyroid Association. 2007; 10.
  117. Sherman SI, Schlumberger MJ, Elisei R, Wirth L, Bastholt L, Droz J, Martins RG, Hofmann M, Locati L, Pacini F, Eschenberg MJ, and Stepan D. Exacerbation of Postsurgical Hypothyroidism During Treatment of Thyroid Carcinoma with Motesanib Diphosphate (AMG 706). ENDO Society 2007. 2007; Abstr #850533.
  118. Wirth L and Kies M. Chemoradiotherapy for Locally-Advanced Head and Neck Cancer. Jennifer Shin, Greg Randolph, and Chris Hartnick, editors. Evidence-Based Otolaryngology In Press. 2007.
  119. Wirth LJ, Posner MR, Tishler RB, Haddad RI, Goguen LA, Clark JR, Allen AM. Phase I study of panitumumab, chemotherapy, and intensity-modulated radiotherapy (IMRT) for head and neck cancer (HNC): Early results. Proc Am Soc Clin Oncol. 2007; 25(18S):Abstr #6083.
  120. Wirth L, Allen AM, Machtay M. Altered fractionation: a fractional benefit? Lancet. 2006 Sep 02; 368(9538):819-21. PMID: 16950339.
    Citations:    Fields:    Translation:Humans
  121. Haddad R, Wirth L, Posner M. Emerging drugs for head and neck cancer. Expert Opin Emerg Drugs. 2006 Sep; 11(3):461-7. PMID: 16939385.
    Citations: 3     Fields:    Translation:HumansAnimals
  122. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner M. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 2006 Jun; 132(6):678-81. PMID: 16785415.
    Citations: 5     Fields:    Translation:Humans
  123. Goguen LA, Posner MR, Norris CM, Tishler RB, Wirth LJ, Annino DJ, Gagne A, Sullivan CA, Sammartino DE, Haddad RI. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Neck Surg. 2006 Jun; 134(6):916-22. PMID: 16730530.
    Citations: 26     Fields:    Translation:Humans
  124. Tishler RB, Posner MR, Norris CM, Mahadevan A, Sullivan C, Goguen L, Wirth LJ, Costello R, Case M, Stowell S, Sammartino D, Busse PM, Haddad RI. Concurrent weekly docetaxel and concomitant boost radiation therapy in the treatment of locally advanced squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2006 Jul 15; 65(4):1036-44. PMID: 16682134.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  125. Goguen LA, Posner MR, Tishler RB, Wirth LJ, Norris CM, Annino DJ, Sullivan CA, Li Y, Haddad RI. Examining the need for neck dissection in the era of chemoradiation therapy for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006 May; 132(5):526-31. PMID: 16702569.
    Citations: 12     Fields:    Translation:Humans
  126. Haddad RI, Posner MR, Busse PM, Norris CM, Goguen LA, Wirth LJ, Blinder R, Krane JF, Tishler RB. Chemoradiotherapy for adenoid cystic carcinoma: preliminary results of an organ sparing approach. Am J Clin Oncol. 2006 Apr; 29(2):153-7. PMID: 16601434.
    Citations: 15     Fields:    Translation:Humans
  127. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med. 2006 Feb 09; 354(6):634-6. PMID: 16467552.
    Citations: 10     Fields:    Translation:Humans
  128. Haddad R, Allen A, Wirth L, Tishler R, Posner M. Integrating novel agents into the curative treatment of head and neck cancer. Expert Rev Anticancer Ther. 2006 Feb; 6(2):157-9. PMID: 16445367.
    Citations: 2     Fields:    Translation:Humans
  129. Posner MR, Haddad RI, Wirth, LJ. The evolution of induction chemotherapy and sequential therapy for locally advanced squamous cell cancer of the head and neck. ASCO Educational Booklet ASCO Atlanta Georgia. 2006; 346-52.
  130. Marshall R. Posner, Robert I. Haddad, and Lori J. Wirth. The evolution of Induction Chemotherapy and Sequential Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck. American Society of Clinical Oncology Education Book. 2006; 42d Annual Meeting:346-353.
  131. Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005 Oct 01; 23(28):6976-81. PMID: 16172459.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  132. Guadagnolo BA, Haddad RI, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Tishler R. Organ preservation and treatment toxicity with induction chemotherapy followed by radiation therapy or chemoradiation for advanced laryngeal cancer. Am J Clin Oncol. 2005 Aug; 28(4):371-8. PMID: 16062079.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  133. Haddad RI, Tishler R, Wirth L, Norris C, Goguen L, Sullivan C, O'Donnell L, Li Y, Posner MR. Rate of complete pathological responses (pCR) to docetaxel/cisplatin/5-fluorouracil (TPF) induction chemotherapy in patients with newly diagnosed, locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2005 Jun; 23(16_suppl):5511. PMID: 27945224.
    Citations:    
  134. Wirth LJ, Moran AE, Krane JF, Weeks L, Norris CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM. Pilot study of celecoxib in oral premalignant lesions (OPLs): Preliminary results. J Clin Oncol. 2005 Jun; 23(16_suppl):1025. PMID: 27944947.
    Citations:    
  135. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005 Jan; 41(1):70-6. PMID: 15598588.
    Citations: 11     Fields:    Translation:Humans
  136. Jati A, Fennesey F, Wirth L, Jacobsen F. Radiographic characteristics of Typical and Atypical Pulmonary Carcinoids: A Single Institution Retrospective Review. Radiological Society of North America. 2005.
  137. Wirth LJ, Moran AE, Krane JF, Weeks L, Norris, CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM . Pilot Study of Celecoxib in Oral Premalignant Lesions (OPLs): Preliminary Results. Proc Am Soc Clin Oncol. 2005; 348.
  138. Posner MR, Wirth L, Tishler RB, Norris CM, Haddad RI. The evolution of induction chemotherapy in locally advanced squamous cell cancer of the head and neck: New paradigm of sequential therapy. DJ Adelstein, editor. Current Clinical Oncology: Squamous Cell Head and Neck Cancer. 2005; 171-186.
  139. Wirth LJ, Moran AE, Krane JF, Weeks L, Norris CM, Goguen LA, Sullivan CA, Haddad RI, Posner MR, Bertagnolli MM. Pilot Study of Celecoxib in Oral Premalignant Lesions (OPLs): Preliminary Results. Proc Am Soc Clin Oncol. 2005; 23(16S):Abstr #1025 .
  140. Posner MR, Haddad RI, Wirth L, Norris CM, Goguen LA, Mahadevan A, Sullivan C, Tishler RB. Induction chemotherapy in locally advanced squamous cell cancer of the head and neck: evolution of the sequential treatment approach. Semin Oncol. 2004 Dec; 31(6):778-85. PMID: 15599855.
    Citations: 13     Fields:    Translation:Humans
  141. Sullivan CA, Jaklitsch MT, Haddad R, Goguen LA, Gagne A, Wirth LJ, Posner MR, Tishler RB, Norris CM. Endoscopic management of hypopharyngeal stenosis after organ sparing therapy for head and neck cancer. Laryngoscope. 2004 Nov; 114(11):1924-31. PMID: 15510015.
    Citations: 10     Fields:    Translation:Humans
  142. Haddad RI, Gokhale AS, Wirth L, Weeks L, Faucher J, Hallar M, Cavacini LA, Posner MR. Interleukin-8 (IL-8) serum levels and squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):9716. PMID: 28016407.
    Citations:    
  143. Wirth LJ, Haddad RI, Wieczorek TJ, Faucher JL, Clark JR, Norris CM, Posner MR. Phase I study of gefitinib plus celecoxib in patients with metastatic and/or locally recurrent squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5540. PMID: 28013989.
    Citations:    
  144. Tishler RB, Haddad RI, Norris CM, Sullivan C, Mahadevan A, Wirth L, Goguen L, Nixon A, Stowell S, Posner MR. A phase I/II study of docetaxel (D) and concomitant boost radiation (CBR) for patients with squamous cell cancer of the head and neck (SCCHN) following induction chemotherapy (IC). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5548. PMID: 28013978.
    Citations:    
  145. Guadagnolo BA, Tishler RB, Posner MR, Weeks L, Wirth LJ, Norris CM, Sullivan CA, Goguen L, Busse PM, Haddad RI. Organ preservation for patients treated with induction chemotherapy (IC) followed by radiation therapy (RT) or chemoradiation (CRT) for advanced stage squamous cell carcinoma of the larynx (SCCL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):5600. PMID: 28015295.
    Citations:    
  146. Wirth LJ, Carter MR, Jänne PA, Johnson BE. Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer. 2004 May; 44(2):213-20. PMID: 15084386.
    Citations: 14     Fields:    Translation:Humans
  147. Haddad R, Wirth L, Costello R, Weeks L, Posner M. Phase II randomized study of concomitant chemoradiation using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Semin Oncol. 2003 Dec; 30(6 Suppl 18):84-8. PMID: 14727246.
    Citations: 1     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  148. Wirth LJ, Haddad RI, Posner MR. Progress and perspectives in chemoprevention of head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):339-55. PMID: 12820777.
    Citations: 1     Fields:    Translation:HumansAnimals
  149. Haddad RI, Wirth L, Posner MR. Integration of chemotherapy in the curative treatment of locally advanced head and neck cancer. Expert Rev Anticancer Ther. 2003 Jun; 3(3):331-8. PMID: 12820776.
    Citations: 3     Fields:    Translation:HumansAnimals
  150. Wirth LJ, Lucca J, Ostler P, Fidias P, Lynch C, Jänne PA, Herbst RS, Johnson BE, Sugarbaker DJ, Mathisen DJ, Lukanich JM, Choi NC, Berman SM, Skarin AT. Induction docetaxel and carboplatin followed by weekly docetaxel and carboplatin with concurrent radiotherapy, then surgery in stage III non-small cell lung cancer: a Phase I study. Clin Cancer Res. 2003 May; 9(5):1698-704. PMID: 12738723.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  151. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA, Posner MR. Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist. 2003; 8(1):35-44. PMID: 12604730.
    Citations: 6     Fields:    Translation:Humans
  152. Kolodner RD, Hall NR, Lipford J, Kane MF, Rao MR, Morrison P, Wirth L, Finan PJ, Burn J, Chapman P. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations. Genomics. 1994 Dec; 24(3):516-26. PMID: 7713503.
    Citations: 37     Fields:    Translation:HumansCells
  153. Kolodner RD, Hall NR, Lipford J, Kane MF, Rao MR, Morrison P, Wirth L, Finan PJ, Burn J, Chapman P, et al. Human mismatch repair genes and their association with hereditary non-polyposis colon cancer. Cold Spring Harb Symp Quant Biol. 1994; 59:331-8. PMID: 7587085.
    Citations: 7     Fields:    Translation:HumansCells
  154. Adra CN, Ko J, Leonard D, Wirth LJ, Cerione RA, Lim B. Identification of a novel protein with GDP dissociation inhibitor activity for the ras-like proteins CDC42Hs and rac I. Genes Chromosomes Cancer. 1993 Dec; 8(4):253-61. PMID: 7512369.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Wirth's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (365)
Explore
_
Co-Authors (110)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.